Downgrade Alert for Cepheid (CPHD)
Cepheid (NASDAQ:CPHD) was downgraded from Buy to Hold at Needham today. The stock closed yesterday at $52.53 on volume of 31.6 million shares, above average daily volume of 788,000.
Cepheid, Inc. develops, manufactures, and markets microfluidic systems for analyzing nucleic acids in blood, urine, and other substances. The Company's technology is designed to detect infinitesimal amounts of disease-causing agents and contaminants in food and water and purify DNA and perform genetic profiling.
Cepheid share prices have moved between a 52-week high of $63.69 and a 52-week low of $25.09 and closed yesterday at 109% above that low price at $52.53 per share. Over the last five market days, the 200-day moving average (MA) has gone down 1.2% while the 50-day MA has declined 0.8%.
Cepheid (NASDAQ:CPHD) defies analysts with a current price ($52.53) 19.9% above its average consensus price target of $42.10. The stock should find initial support at its 200-day moving average (MA) of $37.36 and further support at its 50-day MA of $32.58.
SmarTrend recommended that subscribers consider buying shares of Cepheid on June 20th, 2016 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $29.75. Since that recommendation, shares of Cepheid have risen 15.7%. We continue to monitor CPHD for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.
Keywords: analyst upgrades/downgrades cepheid